Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line

Osimertinib (OSI, also known as AZD9291) is the newest FDA-approved epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for non-small cell lung cancer (NSCLC) patients with EGFR T790M mutation. However, resistance to OSI is likely to progress and the study of potential OSI-resistant me...

全面介紹

Na minha lista:
書目詳細資料
發表在:Oncotarget
Main Authors: Tang, Zheng-Hai, Jiang, Xiao-Ming, Guo, Xia, Fong, Chi Man Vivienne, Chen, Xiuping, Lu, Jin-Jian
格式: Artigo
語言:Inglês
出版: Impact Journals LLC 2016
主題:
Research Paper
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5348415/
https://ncbi.nlm.nih.gov/pubmed/27835594
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13150
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍